KA
NKTR icon

Klingman & Associates’s Nektar Therapeutics NKTR Stock Holding History

Klingman & Associates’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,338
Closed -$79.2K – 202
2022
Q4 		$79.2K Sell
2,338
-34
-1% -$1.65K 0.01% 202
2022
Q3 		$114K Buy
+2,372
New +$141K 0.01% 185

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Klingman & Associates's NKTR Position: Q1 2023 in Review

Klingman & Associates sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 2,338 shares — an estimated $79.2K sold.

Klingman & Associates first reported a position in NKTR in Q3 2022 and held it in 2 quarters. The position peaked at $114K in Q3 2022. 194 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

  • Klingman & Associates reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Klingman & Associates sold 2,338 Nektar Therapeutics shares in Q1 2023, an estimated $79.2K.
  • Klingman & Associates first reported a position in Nektar Therapeutics in Q3 2022 and held it in 2 quarters.
  • Klingman & Associates's Nektar Therapeutics position peaked at $114K in Q3 2022.
  • 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on Klingman & Associates's 13F filing for Q1 2023, filed 3 May 2023.